loading
Kiora Pharmaceuticals Inc stock is traded at $3.31, with a volume of 11,034. It is up +0.61% in the last 24 hours and down -4.61% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.29
Open:
$3.25
24h Volume:
11,034
Relative Volume:
0.43
Market Cap:
$9.77M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.3594
EPS:
-9.2108
Net Cash Flow:
$7.14M
1W Performance:
-11.42%
1M Performance:
-4.61%
6M Performance:
-35.48%
1Y Performance:
-36.04%
1-Day Range:
Value
$3.23
$3.32
1-Week Range:
Value
$3.16
$3.80
52-Week Range:
Value
$3.00
$8.982

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name
Name
Kiora Pharmaceuticals Inc
Name
Phone
781-788-8869
Name
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Name
Employee
12
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
KPRX's Discussions on Twitter

Compare KPRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KPRX 3.3191 9.77M 0 2.81M 7.14M -9.2108
VRTX 467.50 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.42 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.61 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.58 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.64 24.08B 3.30B -501.07M 1.03B 11.54

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

pulisher
Nov 15, 2024

What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World

Nov 15, 2024
pulisher
Nov 15, 2024

ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com

Nov 13, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile

Nov 08, 2024
pulisher
Oct 30, 2024

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance

Oct 29, 2024
pulisher
Sep 25, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN

Sep 25, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com

Sep 12, 2024
pulisher
Aug 23, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World

Aug 23, 2024
pulisher
Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia

Aug 20, 2024
pulisher
Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India

Aug 20, 2024
pulisher
Aug 17, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World

Aug 17, 2024
pulisher
Aug 13, 2024

How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union

Aug 13, 2024
pulisher
Aug 09, 2024

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance

Aug 09, 2024
pulisher
Aug 06, 2024

KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Aug 06, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe

Jul 30, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada

Jul 30, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile

Jul 30, 2024
pulisher
Jul 24, 2024

HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World

Jul 24, 2024
pulisher
Jul 24, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World

Jul 24, 2024
pulisher
Jul 18, 2024

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World

Jul 18, 2024
pulisher
Jul 11, 2024

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 11, 2024
pulisher
Jul 10, 2024

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan

Jul 10, 2024
pulisher
Jul 10, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World

Jul 10, 2024
pulisher
Jul 05, 2024

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 05, 2024
pulisher
Jul 01, 2024

Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com

Jul 01, 2024
pulisher
Jul 01, 2024

Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia

Jul 01, 2024
pulisher
Jul 01, 2024

Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada

Jul 01, 2024
pulisher
Jul 01, 2024

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks

Jul 01, 2024
pulisher
Jul 01, 2024

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com

Jul 01, 2024
pulisher
Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile

Jun 25, 2024
pulisher
Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan

Jun 25, 2024
pulisher
Jun 24, 2024

CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK

Jun 24, 2024
pulisher
Jun 21, 2024

Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com

Jun 21, 2024
pulisher
Jun 20, 2024

KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView

Jun 20, 2024
pulisher
Jun 19, 2024

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow

Jun 19, 2024
pulisher
Jun 19, 2024

Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow

Jun 19, 2024
pulisher
Jun 18, 2024

Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance

Jun 18, 2024
pulisher
Jun 15, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Upgraded to Strong-Buy at Maxim Group - Defense World

Jun 15, 2024

Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Kiora Pharmaceuticals Inc Stock (KPRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Shapiro Aron
Director
Sep 10 '24
Buy
3.60
3,000
10,800
3,000
Walters-Hoffert Lisa
Director
Aug 19 '24
Buy
3.86
1,250
4,825
1,250
TYLE PRAVEEN
Director
Aug 19 '24
Buy
3.96
5,000
19,800
5,014
Tosca Melissa
CFO
Aug 14 '24
Buy
3.21
2,000
6,420
13,599
Tosca Melissa
EVP Finance
Jun 14 '24
Buy
5.25
100
525
3,979
Daniels Eric Joseph
Chief Development Officer
Jun 14 '24
Buy
5.29
1,431
7,570
11,222
Parsons Erin
Director
Jun 13 '24
Buy
4.88
5,260
25,669
5,260
Strem Brian M.
President and CEO
Jun 13 '24
Buy
5.00
3,000
14,997
14,531
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):